디앤디파마텍

347850KOSDAQ자연과학 및 공학 연구개발업

41.5 / 100

Reference Date: 2026-04-13

Financial Score11.0 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Plunged 19.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

D&D Pharmatech is a biopharmaceutical company specializing in developing innovative drugs for metabolic diseases, such as obesity and MASH (metabolic-associated steatohepatitis), and neurodegenerative disorders like Parkinson's and Alzheimer's, leveraging GLP-1-based peptide technology. The company's key pipelines include oral weight-loss medications and MASH treatments, with a business model focused on licensing and co-development with global partners. Additionally, it expands into areas such as PET biomarker development and alpha radiation-based cancer therapies through its subsidiaries.

Number of Employees

22people

Average Salary

169.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-32.29Industry Average -32.113.5Point

In line with industry avg

Debt Ratio

16.64Industry Average 7.520.0Point

2.2x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼62.4% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼35.9% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -39.8% (improving, 2yr)

Detailed News Sentiment

3 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (63%)

Current 74,000Won52-week high 110,00052-week low 12,099

1-month return0.0Point

1m -19.83% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
Neutral정기주주총회결과2026-03-30
Neutral감사보고서제출2026-03-20
Neutral사업보고서 (2025.12)2026-03-20